JUL 07, 2016 5:17 AM PDT

Scientists Reinvent Beta-Blockers to Treat Heart Failure

WRITTEN BY: Kara Marker
Traditional beta-blockers target beta1-adrenergic receptors, which helps to prevent heart cells from dying and exacerbating a case of heart failure. However, beta1-adrenergic are also responsible for helping the heart to continue pumping blood to carry oxygen to the body tissues. For the almost six million Americans who suffer from heart failure, scientists were desperately seeking out a way to improve beta-blockers to both save dying heart cells and preserve the pumping abilities of the heart muscle. For scientists from Thomas Jefferson University, this discovery and much more followed after careful experimentation.
Selective activation of the beta2-adrenergic receptor by a beta-arrestin-biased pepducin promotes activation of a beta-arrestin signaling pathway
The Thomas Jefferson University researchers found their solution by altering the target pathway of beta-blockers. Rather than targeting beta1-adrenergic receptors, they designed a molecule called a "pepducin," which was created from partsof the beta2-adrenergic receptor. Pepducins, they found, naturally activates beta2-adrenergic receptors and only these receptors, potentially bypassing the negative effect beta-blockers have on the pumping action of the heart without giving up on saving dying heart cells.

The alternate pathway of treating heart failure, said senior author of the study Jeffrey Benovic, PhD, is "an excellent example of how a little curiosity in the basic research laboratory can lead to discoveries that have  the potential to change the way we treat a very common and very deadly illness." The Centers for Disease Control and Prevention estimate that half of all people with heart failure will die from the disease within five years.

The discoveries didn't stop with pepducins and beta2-adrenergic receptors. While studying the structure of pepducins in finer detail, one of the team scientists noticed that the pepducins they had designed looked a lot like an existing treatment for heart failure, a drug called carvedilol. This drug targets both beta-1 and beta-2 adrenergic receptors as well as alpha-receptors to lower blood pressure, relax arteries, and even acts as an antioxidant, eliminating free radicals in the blood. Realizing the similarities between pepducins and carvedilol pushed the scientists to dive even further into the true power of pepducins. What they found was astronishing.

They discovered that pepducins not only preserved the beating abilities of cardiomyocytes, but they enhanced the force of the beating to a higher level. This discovery was especially shocking because until now, researchers were not aware that beta2-adrenergic receptors were capable of impacting the beating function of the heart. Since pepducins uniquely activate beta2-adrenergic receptors, they knew it was this pathway that was stimulating the forceful heart beat. 

Next the identified a secondary signaling molecule called beta-arrestin as the intermediary force behind the heart cells beating, with activation of pepducins leading to contraction of cardiomyocytes increased by up to 50 percent. However, with the right tweaking, researchers from the study believe they could get pepducins enhancing cardiomyocyte contraction up to a full 100 percent. 

"If we find or design a compound that works like this pepducin, it wouldn't necessarily cure heart disease, but it would give doctors another tool to help bolster a failing heart," Benovic said. He and his team are now working on improving pepducin before bringing it into clinical trials. It may be a little while longer, but it seems as if the future of heart failure treatment is on the way.

This study was recently published in the Proceedings of the National Academy of Sciences.
 


Sources: Thomas Jefferson University, CDC, CHFpatients.com
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JAN 19, 2020
Cell & Molecular Biology
JAN 19, 2020
Scientists Create Neuromuscular Organoids That Contract
This work is a breakthrough for the study of neuromuscular diseases including ALS, muscular dystrophy and multiple sclerosis....
JAN 29, 2020
Cannabis Sciences
JAN 29, 2020
In Sicily, Medical Cannabis Is Now Free
The Sicilian government will now foot the bill for many patients using medical cannabis. Sicily’s top health administrator, Ruggero Razza, announced...
FEB 18, 2020
Cell & Molecular Biology
FEB 18, 2020
How Too Much Fluoride Can Disrupt Tooth Enamel
You can have too much of a good thing....
FEB 24, 2020
Clinical & Molecular DX
FEB 24, 2020
Nanoparticles provide momentum for better diagnostic imaging
Photoacoustic imaging is an emerging tool with a vast array of biomedical applications ranging from the detection of brain lesions to imaging early signs o...
FEB 21, 2020
Cardiology
FEB 21, 2020
Longer Sitting Times Linked to Developing Heart Disease
Longer sitting times has been associated with a higher risk of developing heart disease among overweight and obese women following menopause. For the study...
FEB 24, 2020
Cancer
FEB 24, 2020
Could NRF2 trigger hepatomegaly?
Research published today in the Journal of Hepatology suggests that the protein responsible for antioxidant defenses in humans may adversely affect th...
Loading Comments...